Top 500 market capitalization in the first quarter of 2018: Hengrui HENGQIANG, Shiyao, China biological advanced 100 billion market capitalization, Baiji Shenzhou, and Taige pharmaceutical rising strongly

Source: from April 19, 2018 to the first quarter of 2018, major events occurred frequently in the pharmaceutical industry, affecting the development of the industry According to wind data, 36 pharmaceutical listed companies entered the top 500 market value in the first quarter Among them, there are six hundred billion enterprises in total Compared with the four enterprises at the end of 2017, the new group of petrochemicals and China biopharmaceutical group are added Among them, Baiji Shenzhou and tiger medicine ranked higher (Note: manual data filtering, if there is any omission, please leave a message at the end of the article to supplement.) Hengrui HENGQIANG continued to develop steadily in 2018 The market value of Hengrui medicine in the first quarter increased by 26.86% compared with that at the end of 2017, with a total market value of 246.5 billion Hengrui has been a leader in listed pharmaceutical enterprises, with strong comprehensive strength According to drug intelligence data, Hengrui has 979 drug application records since 2001, including 536 new drugs, accounting for 54.75% Among them, there are 42 new drugs of class 1 (calculated by acceptance number, the same below), 78 new drugs of class 1.1, 62 have been approved for clinical use and 6 have been approved for production It is self-evident that Hengrui has the ability to develop new drugs Several important innovative drugs in Hengrui's R & D pipeline are worth looking forward to: thiopefigeristine (19K) for neutropenia, shr-1210 (camrelizumab) for multiple solid tumors, pyrrolidine maleate for HER2 positive breast cancer, ramazolam for anesthesia, regolidin for type 2 diabetes, famitinib for colorectal cancer, and diabetes mellitus type 2 diabetes Praline henggliptine in the disease, haiqubopa ethanolamine in the treatment of immune thrombocytopenia and shr6390 in the treatment of breast cancer Among them, it is expected that in 2018, tiopefigeristine (19K), pyrrolidine maleate and rimazolum will be on the market In the first quarter, Hengrui continued to develop steadily, but at the beginning of the second quarter, Hengrui experienced twists and turns because of the linkage of policies On April 12, the State Council announced that it would implement zero tariff on anti-cancer drugs on May 1, and a number of domestic anti-cancer drug enterprises including Fosun Pharmaceutical, Kelun, LVYE, Beida, Lizhu, Shuanglu, etc fell in response By the end of April 13, Hengrui had declined by 4.64%, and the market value of Hengrui A shares had evaporated by 11 billion yuan in half a day, which attracted the industry's surprise The impact of the policy fluctuation is temporary, Hengrui's layout in the industry development has been relatively stable, and Hengrui's innovation and R & D ability has been strong On the basis of policies encouraging the development of innovative drugs, we believe that Hengrui's positive response will soon be able to make up for the loss Shiyao group, dadimeda Pharmaceutical Group Co., Ltd has three business segments, i.e innovative medicine, general medicine and API The company's development route has always been the representative of domestic large-scale medicine The company's products mainly include antibiotics, cardiovascular and cerebrovascular drugs, antipyretic and analgesic drugs, digestive system drugs, anti-tumor drugs and Chinese patent medicines, among which enbep, olanin, Xuanning, dometil, jinyuli and nolinine are the best-selling innovative drug products in China According to the data of pharmaceutical intelligence, there are 165 new drugs under research (calculated by acceptance number, the same below), 12 new drugs of class 1, and 6 new drugs of class 1.1 are approved clinically (as shown in the figure below) In addition, in the field of generic drugs, the group also has strong competitiveness On the latest February 12, 2018, the production approval of paclitaxel for injection (albumin binding type) for the treatment of breast cancer, lung cancer, pancreatic cancer, etc was obtained, which was the first successful imitation before Hengrui This drug is a key variety of new base in the United States It was launched in the United States in 2005 In addition, it is expected that by the end of 2018, the group will also have 10 high-end generic drugs such as dronedarone hydrochloride tablets and metformin hydrochloride tablets on the market At the beginning of April, azithromycin tablets (0.25g / 0.5g) produced by Ouyi Pharmaceutical Co., Ltd of Shiyao group passed the consistency evaluation of generic drugs, becoming the first domestic enterprise that passed the consistency evaluation of azithromycin tablets, further improving the market competitiveness of the company China biopharmaceutical, the leading enterprise of China biopharmaceutical and generic medicine, is mainly engaged in the research, development, production and sales of a series of modern Chinese medicine preparations and chemicals for the treatment of liver disease and cardiovascular and cerebrovascular diseases Subsidiary Zhengda Tianqing is the top five pharmaceutical companies in China, and the company's original research capacity ranks first in China In 2017, China's biopharmaceutical performance was good According to the annual report, 32 single products sold over 100 million yuan, and the R & D has not been disconnected In 2017, the R & D expenses reached 1.595 billion yuan In 2018, China's biopharmaceuticals made strong progress In the first quarter, on January 10, its subsidiary Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd passed the consistency evaluation of Tuotuo (rosuvastatin calcium) tablet; on March 28, irumbin (Irbesartan / hydrochlorothiazide) tablet also passed the consistency evaluation It has opened up a good market competitiveness of generic drugs Under the favorable environment of domestic generic drug policy, the market value of China's biopharmaceutical industry has risen In addition, it is estimated that in 2018, its subsidiaries, Zhengda Tianqing's blockbuster generic injection of bendamostine hydrochloride and ganaric acetate injection, etc., may be listed Baiji Shenzhou, mystery and myth Baiji Shenzhou was listed in the United States against the trend in 2016 A mystery company that has been established for 5 years without product listing appeared in the public vision in this way In the next two years, the market value of Baiji increased six times, creating a myth Baiji Shenzhou became a unicorn in the field of biomedical innovation The reason for such achievements is inseparable from the rich R & D pipeline of Baiji Shenzhou and a series of strategic cooperation with Xinji, an international pharmaceutical giant In the first quarter of 2018, Baiji Shenzhou was even more active On January 16, Baiji Shenzhou announced a new round of stock public offering plan On January 22, it raised about $800 million, the third largest amount in the world's biotechnology field in five years Baiji Shenzhou has been committed to the investment of innovative drugs According to the 2017 performance report, the company's R & D cost is US $269.02 million (about RMB 1.7 billion), with an average growth rate of over 150% in the past three years In addition, with the rapid development of policies, innovative drugs developed locally can start clinical trials in China and around the world simultaneously, which makes the rapid development of Baiji Shenzhou At present, the company has 7 drugs in clinical stage, all of which are cutting-edge and hot projects in the field of global new drug research and development, including the second generation Btk inhibitor zanubrutinib (bgb-3111), humanized PD-1 monoclonal antibody tislilizumab (bgb-a317), PARP1 and PARP2 small fraction inhibitor pamiparib (bgb-290) Recently, tislilizumab (bgb-a317), a PD-1 antibody independently developed by Baiji Shenzhou, has achieved the first patient administration in a global phase 3 clinical trial as a potential second-line treatment for patients with advanced non resectable or metastatic esophageal squamous cell carcinoma (ESCC) In addition, according to drug intelligence data, (bgb-a317) is used in global phase 3 clinical trials for patients with non-small cell lung cancer and liver cancer, and phase 2 clinical trials for patients with recurrent / refractory classic Hodgkin's lymphoma and patients with urothelial cancer are also in progress in China Kingsley biotechnology, a technology that promotes the rapid development of Kingsley biotechnology, can be said to have shocked the industry Since it went public at the end of 2015, its rising momentum has not stopped The main reason for the sharp rise lies in its mastery of a technology, the extremely popular car-t technology in recent years Car-t, full name is chimeric antigen receptor T-cell immunotherapy Similar to other immunotherapies, its basic principle is to use the patient's own immune cells to remove cancer cells In the world, the development of car-t is led by the United States Novartis, kit and Juno are at the forefront of the research and development of car-t therapy Two of the products have been approved by FDA for listing In China, clinical research has developed rapidly, especially Kingsley legend Car-t therapy of its Nanjing legend Biotechnology Co., Ltd has been approved to enter the formal clinical practice first, and the clinical application of Beijing yisec Medical Co., Ltd has also been undertaken in February In addition, bosengji, Keji biology, Hengrun Dasheng, Chengdu galaxy, etc have also applied for clinical practice in succession It is worth mentioning that in the development of car-t, Kingsley legend not only amazed its peers in clinical research data, but also envied the industry for its strategic cooperation with pharmaceutical giant Johnson & Johnson At the end of 2017, Kingsley and Johnson & Johnson of the United States reached a global license and cooperation agreement on car-t therapy of legendary biology targeting BCMA for multiple myeloma Johnson & Johnson paid Kingsley $350 million in initial payment and subsequent milestone payment, and jointly developed the global market (with 7:3 market share in China, 7:7 share in Kingsley; 5:5 share in other markets) This cooperation Set the maximum down payment amount and the best cooperation conditions for Chinese pharmaceutical enterprises to grant foreign patents Tiger Pharma, innovative cro tiger Pharma, previously known as "innovative cro" for participating in more than 80 clinical trials of domestic innovative drugs, has 33 subsidiaries In the first quarter of 2018, tiger pharmaceutical developed well According to the latest first quarter performance forecast, the net profit attributable to shareholders of Listed Companies in the current quarter is expected to be 91.103 million yuan - 99.7795 million yuan, an increase of 110% - 130% over the same period of last year According to the pharmaceutical intelligence data, tag pharmaceutical has 146 drug applications in CDE (based on the acceptance number, the same below), including 123 imported drugs, 1 re registration for import, 12 supplementary applications and 5 reexamination Its fpa144 injection and ekuzumab injection are worth looking forward to In addition, 21 clinical trials of tiger medicine have entered phase 3 Note: some information comes from the Internet